A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Neuren Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Rett Syndrome

Treatments

Drug: Placebo

Drug: NNZ-2566

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01703533

Neu-2566-RETT-001

Details and patient eligibility

About

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.

Full description

Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment.

Enrollment

67 patients

Sex

Female

Ages

16 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of Rett Syndrome with proven mutation of the MeCP2 gene
Age 16 to 45 years
Severity rating of between 10 and 36 (Rett Syndrome Natural History/Clinical Severity Scale)
Concomitant medications must be stable for >4 weeks prior to enrollment. The following concomitant medications are permitted: anticonvulsants which do not have liver inducing effects; beta-blockers; medications for the treatment of gastroesophageal reflux disease (GERD); medications for the treatment of chronic respiratory conditions such as asthma; medications for the treatment of anxiety, of depression and of psychosis, hormonal contraceptives. Melatonin for difficulties with sleep onset.
Ability to swallow study medication provided as a liquid solution, or via gastrostomy tube

Exclusion criteria

No detectable abnormality of the EEG during screening period
Actively undergoing regression
QTcF exclusions (any of the following): baseline/screening QT/QTcF interval of 450 msec; history of risk factors for torsade de pointes (e.g. heart failure, hypokalemia (serum potassium at screening < 3.0 mmol/L) or family history of long QT syndrome; QT/QTcF prolongation previously or currently controlled with medication
Current treatment with insulin
Hgb A1C values outside the normal reference range at screening
Current or past treatment with IGF-1
Current or past treatment with growth hormone
Current treatment with N-methyl-D-aspartate (NMDA) antagonists
Current or planned use of non-medication based interventional therapy during the period of the study (defined as 4-6 week screening period followed by 4 week dosing and 2 week follow-up period)
Current clinically significant cardiovascular, renal, hepatic or respiratory disease
Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the the study medication
History of, or current cerebrovascular disease or brain trauma
History of, or current significant endocrine disorder e.g. hypo or hyperthyroidism or diabetes mellitus
History of, or current malignancy
Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at screening or baseline
Confirmed pregnancy
Significant hearing and/or visual impairment that may affect ability to complete the test procedures
Enrollment in another clinical trial within the previous 30 days
Previously randomized in this clinical trial
Allergy to strawberries